natgillin/translations-raw huggingface dataset:
A value above the normal range may reflect residual active dabigatran or other clinical conditions e.g., presence of other drugs or transfusion coagulopathy. 
Vrijednost iznad normalnog raspona može odražavati rezidualnu aktivnost dabigatrana ili druga klinička stanja, npr. prisutnost drugih lijekova ili transfuzijsku koagulopatiju.
What Praxbind is and what it is used for 2. 
Što je Praxbind i za što se koristi 2.
Thrombin generation parameters 
Parametri stvaranja trombina
Idarucizumab effectively and rapidly reversed the life-threatening bleeding within 15 min after the injection. 
Idarucizumab je učinkovito i brzo poništio po život opasno krvarenje unutar 15 minuta nakon injekcije.
Praxbind does not affect any functions in the body as such, so your doctor may decide to give you this medicine, if the expected benefits outweigh any potential risks. 
Sam Praxbind ne utječe na funkcije u tijelu, stoga liječnik može odlučiti da Vam propiše ovaj lijek, ako očekivane koristi nadilaze sve potencijalne rizike.
There is no clinical experience with overdoses of Praxbind. 
Nema kliničkog iskustva s predoziranjem Praxbindom.
Praxbind is for single-use only and does not contain preservatives (see section 6.3). 
Praxbind je namijenjen samo za jednokratnu uporabu i ne sadrži konzervanse (vidjeti dio 6.3).
Praxbind treatment can be used in conjunction with standard supportive measures, which should be considered as medically appropriate. 
Liječenje Praxbindom može se primijeniti zajedno sa standardnim suportivnim mjerama, koje se smatraju medicinski odgovarajućima.
Reproductive and developmental toxicity studies have not been performed, given the nature and the intended clinical use of the medicinal product. 
Ispitivanja reproduktivne i razvojne toksičnosti nisu izvođena s obzirom na vrstu i namijenjenu kliničku primjenu ovog lijeka.
Based on pharmacokinetic data from 12 patients with liver disease, the AUC of idarucizumab was increased by 10% as compared to patients without liver disease. 
Na temelju farmakokinetičkih podataka u 12 bolesnika s bolešću jetre, AUC idarucizumaba bio je povišen za 10% u usporedbi s onim u bolesnika bez bolesti jetre.
The investigated population consisted of healthy subjects and subjects exhibiting specific population characteristics covering age, body weight, race, sex and renal impairment. 
Ispitivana populacija sastojala se od zdravih dobrovoljaca te ispitanika koji su pokazivali specifične karakteristike populacije s obzirom na dob, tjelesnu težinu, rasu, spol i oštećenje bubrega.
What Praxbind looks like and contents of the pack 
Kako Praxbind izgleda i sadržaj pakiranja
The majority of the patients showed sustained reversal of dabigatran plasma concentrations up to 12 hours (≥90%). 
Većina bolesnika pokazala je održano poništenje plazmatskih koncentracija dabigatrana do 12 sati (≥ 90%).
For additional instructions for use and handling see section 6.6. 
Za dodatne upute o primjeni i rukovanju vidjeti dio 6.6.
Prior to use, the unopened vial may be kept at room temperature (up to 30°C) for up to 48 hours, if stored in the original package in order to protect from light. 
Neotvorena bočica može se prije uporabe čuvati na sobnoj temperaturi (do 30°C) do 48 sati, ako se čuva u originalnom pakiranju kako bi se zaštitila od svjetlosti.
RE-VERSE AD included data for 503 patients: 301 patients with serious bleeding (Group A) and 202 patients requiring an urgent procedure/surgery (Group B). 
Ispitivanje RE-VERSE AD uključivalo je podatke za 503 bolesnika: 301 bolesnika s ozbiljnim krvarenjem (skupina A) i 202 bolesnika kojima je bio potreban hitan postupak/kirurški zahvat (skupina B).
Other medicines and Praxbind 
Drugi lijekovi i Praxbind
Please note this medicine is mainly used in emergency situations and the doctor will have decided that you needed it. - Keep this leaflet. 
Napominjemo da se ovaj lijek uglavnom primjenjuje za hitne situacije, a liječnik će odlučiti treba li Vam lijek.
Mild symptoms of potential hypersensitivity (pyrexia, bronchospasm, hyperventilation, rash or pruritus) were reported. 
Prijavljeni su blagi simptomi potencijalne preosjetljivosti (pireksija, bronhospazam, hiperventilacija, osip ili pruritus).
Praxbind is used in adults in emergency situations where your doctor decides that rapid inactivation of the effect of Pradaxa is required - For emergency surgery/urgent procedures - In life-threatening or uncontrolled bleeding. 
Praxbind se koristi u odraslih u hitnim situacijama kada Vaš liječnik odluči da je potrebno brzo poništenje učinka Pradaxe: - za hitne kirurške zahvate/hitne postupke - u slučaju po život opasnog ili nekontroliranog krvarenja.
A pre-existing intravenous line may be used for administration of Praxbind. 
Već postojeća intravenska linija može se upotrijebiti za primjenu Praxbinda.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user. 
Ako se lijek ne upotrijebi odmah, korisnik je odgovoran za vrijeme i uvjete čuvanja prije uporabe.
The recommended dose of Praxbind contains 4 g sorbitol as an excipient. 
Preporučena doza Praxbinda sadrži 4 g sorbitola kao pomoćnu tvar.
The European Medicines Agency has deferred the obligation to submit the results of studies with Praxbind in one or more subsets of the paediatric population in the prevention and treatment of dabigatran associated haemorrhage (see section 4.2 for information on paediatric use). 
Europska agencija za lijekove odgodila je obvezu podnošenja rezultata ispitivanja lijeka Praxbind u jednoj ili više podskupina pedijatrijske populacije u prevenciji i liječenju krvarenja povezanog s dabigatranom (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
All nine patients were redosed within 6 days after the first idarucizumab dose. 
Svih devet bolesnika ponovno je primilo dozu unutar 6 dana nakon prve doze idarucizumaba.
Studies to evaluate the mutagenic and carcinogenic potential of idarucizumab have not been performed. 
Ispitivanja u svrhu procjene mutagenog i karcinogenog potencijala idarucizumaba nisu provedena.
If Praxbind is administered in these patients, intensified medical care during Praxbind exposure and within 24 hours of exposure is required. 
Ako se Praxbind primjenjuje u ovih bolesnika, potrebna je intenzivirana medicinska skrb tijekom izloženosti Praxbindu i unutar 24 sata nakon izloženosti.
A key secondary endpoint was the restoration of haemostasis. 
Ključna sekundarna mjera ishoda bila je obnova hemostaze.
• other anticoagulants (e.g. thrombin inhibitors other than dabigatran, Factor Xa inhibitors including low-molecular weight heparin, vitamin K-antagonists, heparin). 
• drugim antikoagulansima (npr. inhibitorima trombina osim dabigatrana, inhibitorima faktora Xa uključujući heparin niske molekulske mase, antagoniste vitamina K, heparin).
It will not reverse the effects of other anticoagulants (see section 5.1). 
On neće poništiti učinke drugih antikoagulansa (vidjeti dio 5.1).
Following the intravenous infusion of a 5 g dose, the geometric mean volume of distribution at steady state (Vss) was 8.9 L (geometric coefficient of variation (gCV) 24.8 %). 
Nakon intravenske infuzije doze od 5 g, geometrijski srednji volumen distribucije pri stanju dinamičke ravnoteže (Vss) bio je 8,9 l (geometrijski koeficijent varijacije (gCV) 24,8%).
Administration of a second 5 g dose of Praxbind may be considered in the following situations: 
Primjena druge doze Praxbinda od 5 g može se razmotriti u sljedećim situacijama:
This medicine is for hospital use only. 
Ovaj lijek je samo za bolničku primjenu.
61.5% of patients in Group A and 62.4% of patients in Group B had been treated with dabigatran 110 mg twice daily. 
61,5% bolesnika u skupini A te 62,4% bolesnika u skupini B liječeno je dabigatranom 110 mg dvaput dnevno.
The idarucizumab formulation did not produce haemolysis of human whole blood in vitro. 
Formulacija idarucizumaba nije dovela do hemolize humane pune krvi in vitro.
Praxbind must not be mixed with other medicinal products. 
Praxbind se ne smije miješati s drugim lijekovima.
Idarucizumab is produced by recombinant DNA technology in Chinese Hamster Ovary cells. 
Idarucizumab je proizveden tehnologijom rekombinantne DNK u stanicama jajnika kineskog hrčka.
This medicine contains 50 mg sodium (main component of cooking/table salt) per dose. 
Ovaj lijek sadrži 50 mg natrija (glavnog sastojka kuhinjske soli) po dozi.
In Phase I studies Praxbind has been investigated in subjects with a creatinine clearance ranging from 44 to 213 mL/min. 
U ispitivanjima faze I Praxbind se ispitivao u osoba s klirensom kreatinina u rasponu od 44 do 213 ml/min.
For storage conditions after opening of the medicinal product, see section 6.3. 
Uvjete čuvanja nakon prvog otvaranja lijeka vidjeti u dijelu 6.3.
Based on these data and the extent of reversal of the anticoagulant effect of dabigatran in patients, renal impairment does not impact the reversal effect of idarucizumab. 
Na temelju ovih podataka i opsega antikoagulacijskog učinka dabigatrana u bolesnika, oštećenje bubrega ne utječe na antagonistički učinak idarucizumaba.
Pradaxa can be given again 24 hours after Praxbind administration. 
Pradaxa se može ponovo dati 24 sata nakon primjene Praxbinda.
Praxbind is for single-use only and does not contain preservatives. 
Praxbind je namijenjen samo za jednokratnu uporabu i ne sadrži konzervanse.
This medicine will only remove dabigatran from your body. 
Ovaj lijek će iz Vašeg tijela ukloniti samo dabigatran.
Tell your doctor, if you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby. 
Ako ste trudni ili dojite, mislite da biste mogli biti trudni ili planirate imati dijete, obratite se svom liječniku.
Based on population pharmacokinetic analyses, sex, age, and race do not have a clinically meaningful effect on the pharmacokinetics of idarucizumab. 
Na osnovi farmakokinetičkih analiza populacije, spol, dob i rasa nemaju klinički značajan učinak na farmakokinetiku idarucizumaba.
In patients with hereditary fructose intolerance, parenteral administration of sorbitol has been associated with reports of hypoglycemia, hypophosphatemia, metabolic acidosis, increase in uric acid, acute liver failure with breakdown of excretory and synthetic function, and death. 
U bolesnika s nasljednom nepodnošljivošću fruktoze parenteralna primjena sorbitola je povezana s prijavljenim slučajevima hipoglikemije, hipofosfatemije, metaboličke acidoze, povećanja mokraćne kiseline, akutnog zatajenja jetre s prekidom ekskretorne i sintetske funkcije, kao i smrti.
This occurred 1-24 hours after administration of idarucizumab mainly at timepoints ≥12 hours. 
To se javilo 1-24 sata nakon primjene idarucizumaba uglavnom na vremenskim točkama ≥ 12 sati.
There is no information on the effects of this medicine in pregnant or breast-feeding women. 
Nema podataka o učincima ovog lijeka u trudnica ili dojilja.
The transient proteinuria is not indicative of renal damage, which should be taken into account for urine testing. 
Prolazna proteinurija ne upućuje na oštećenje bubrega što treba uzeti u obzir pri pretrazi urina.
One prospective, open-label, non-randomized, uncontrolled study (RE-VERSE AD) was conducted to investigate the treatment of adult patients who presented with dabigatran-related life-threatening or uncontrolled bleeding (Group A) or who required emergency surgery or urgent procedures (Group B). 
Provedeno je jedno prospektivno, otvoreno, nerandomizirano, nekontrolirano ispitivanje (RE-VERSE AD) kako bi se ispitalo liječenje odraslih bolesnika koji su imali po život opasno stanje ili nekontrolirano krvarenje, a vezano uz primjenu dabigatrana (skupina A) ili im je bio potreban hitni kirurški zahvat ili hitni postupci (skupina B).
This medicine has been designed to only bind to dabigatran. 
Ovaj lijek je razvijen samo u svrhu vezanja za dabigatran.
Hereditary fructose intolerance 
Nasljedna nepodnošljivost fruktoze
It is a humanized monoclonal antibody fragment (Fab) that binds to dabigatran with very high affinity, approximately 300-fold more potent than the binding affinity of dabigatran for thrombin. 
To je fragment humaniziranog monoklonskog antitijela (Fab) koji se za dabigatran veže vrlo visokim afinitetom, približno 300 puta potentnije od afiniteta vezivanja dabigatrana za trombin.
88397 Biberach an der Riss GERMANY 
88397 Biberach an der Riss NJEMAČKA
To reduce this risk, resumption of anticoagulant therapy should be considered as soon as medically appropriate (see section 4.2). 
Radi smanjenja ovog rizika, potrebno je razmotriti nastavljanje terapije antikoagulansom čim je to medicinski prikladno (vidjeti dio 4.2).
In these studies the doses of idarucizumab ranged from 20 mg to 8 g and the infusion times ranged from 5 minutes to 1 hour. 
Doze idarucizumaba u ovim ispitivanjima varirale su od 20 mg do 8 g, a trajanje infuzije od 5 minuta do 1 sata.
Idarucizumab was rapidly eliminated with a total clearance of 47.0 mL/min (gCV 18.4 %), an initial half-life of 47 minutes (gCV 11.4 %) and a terminal half-life of 10.3 h (gCV 18.9 %). 
Idarucizumab se brzo eliminirao uz ukupni klirens od 47,0 ml/min (gCV 18,4%), početni poluvijek od 47 minuta (gCV 11,4%) i terminalni poluvijek od 10,3 h (gCV 18,9%).
After intravenous administration of 5 g idarucizumab, 32.1 % (gCV 60.0 %) of the dose was recovered in urine within a collection period of 6 hours and less than 1 % in the following 18 hours. 
Nakon intravenske primjene 5 g idarucizumaba, 32,1% (gCV 60,0%) doze se pojavilo (engl. recovered) u urinu unutar perioda prikupljanja od 6 sati, a manje od 1% u sljedećih 18 sati.
A trauma model in pigs was performed using a blunt liver injury after dosing with dabigatran to achieve supratherapeutic concentrations of about 10-fold of human plasma levels. 
Model traume je izveden na svinjama primjenom tupe ozljede jetre nakon doziranja dabigatranom s ciljem postizanja supraterapijskih koncentracija od oko 10-puta viših od razina u humanoj plazmi.
Studies to assess the potential reproductive effects of idarucizumab have not been performed. 
Ispitivanja u svrhu ocjene potencijalnih učinaka idarucizumaba na reprodukciju nisu provedena.
If an anaphylactic reaction or other serious allergic reaction occurs, administration of Praxbind should be discontinued immediately and appropriate therapy initiated. 
Ako se pojavi anafilaktička reakcija ili druga ozbiljna alergijska reakcija, potrebno je odmah prekinuti primjenu Praxbinda i započeti odgovarajuću terapiju.
50 mL solution in a glass vial (type I glass), with a butyl rubber stopper, an aluminium cap and a label with integrated hanger. 
50 ml otopine u staklenoj bočici (staklo tipa I) sa čepom od butilne gume, aluminijskim zatvaračem i naljepnicom s integriranom vješalicom.
Thromboembolic Events 
Tromboembolički događaji
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V. 4.9 Overdose 
Od zdravstvenih radnika se traži da prijave svaku sumnju na nuspojavu lijeka putem nacionalnog sustava prijave nuspojava: navedenog u Dodatku V.
Most patients in both Groups A and B, achieved complete reversal of the anticoagulant effect of dabigatran (dTT: 98.7%; ECT: 82.2%; aPTT: 92.5% of evaluable patients, respectively) in the first 4 hours after administration of 5 g idarucizumab. 
Većina bolesnika, u obje skupine, A i B, postigli su potpuno poništenje antikoagulacijskog učinka dabigatrana (dTT: 98,7%; ECT 82,2%; aPTT: 92,5% bolesnika koji su se mogli procijeniti) u prva 4 sata nakon primjene 5 g idarucizumaba.
• if potential re-bleeding would be life-threatening and prolonged clotting times are observed, or 
• ako bi potencijalno ponovno krvarenje bilo po život opasno, a opažena su produljena vremena zgrušavanja ili
Based on pharmacokinetic data from 347 patients with different degrees of renal function (median creatinine clearance 21 - 99 mL/min) it is estimated that mean idarucizumab exposure (AUC0-24h) increases by 38% in patients with mild (CrCl 50-<80 mL/min), by 90% in moderate (30-<50 mL/min) and by 146% in severe (0-<30 mL/min) renal impairment. 
Na temelju farmakokinetičkih podataka od 347 bolesnika s različitim stupnjevima bubrežne funkcije (medijan klirensa kreatinina 21-99 ml/min) procijenjeno je da se srednja izloženost idarucizumabu (AUC0-24 h) povećava za 38% u bolesnika s blagim (CrCl 50-<80 ml/min), za 90% u bolesnika s umjerenim (30-<50 ml/min) i za 146% u bolesnika s teškim (0-<30 ml/min) oštećenjem bubrega.
Praxbind is a reversal agent specific for dabigatran (Pradaxa), a blood thinner medicine that blocks a substance in the body, which is involved in blood clot formation. 
Praxbind je antagonist specifičan za dabigatran (Pradaxu), lijek za razrjeđivanje krvi koji blokira tvar u tijelu uključenu u stvaranje krvnog ugruška.
After you have received Praxbind, your doctor will decide on the continuation of your treatment to prevent blood clot formation. 
Nakon što ste primili Praxbind, Vaš će liječnik odlučiti o nastavljanju liječenja radi sprječavanja stvaranja krvnih ugrušaka.
A complete and sustained reversal of dabigatran-induced clotting time prolongation was observed immediately after the idarucizumab infusion, lasting over the entire observation period of at least 24 h. 
Potpuno i održano poništenje produljenja vremena zgrušavanja induciranog dabigatranom zapaženo je odmah nakon infuzije idarucizumaba i trajalo je tijekom cijelog razdoblja praćenja od najmanje 24 h.
After opening the vial, chemical and physical in-use stability of idarucizumab has been demonstrated for 6 hours at room temperature. 
Nakon otvaranja bočice, kemijska i fizikalna stabilnost idarucizumaba tijekom uporabe pokazana je za 6 sati na sobnoj temperaturi.
Idarucizumab exhibited multiphasic disposition kinetics and limited extravascular distribution. 
Idarucizumab je pokazao kinetiku dispozicije u više faza i ograničenu ekstravaskularnu distribuciju.
No dose adjustment is required in elderly patients aged 65 years and above (see section 5.2). 
Nije potrebna prilagodba doze u bolesnika starijih od 65 godina (vidjeti dio 5.2).
D-88397 Biberach an der Riss Germany 
D-88397 Biberach an der Riss Njemačka
Representative values for pharmacokinetic and pharmacodynamics parameters were established on the basis of healthy subjects aged 45-64 years receiving 5 g idarucizumab (see sections 5.1 and 5.2). 
Reprezentativne vrijednosti za farmakokinetičke i farmakodinamičke parametre ustanovljene su na temelju zdravih dobrovoljaca u dobi od 45-64 godina koji su primili 5 g idarucizumaba (vidjeti dijelove 5.1 i 5.2).
• recurrence of clinically relevant bleeding together with prolonged clotting times, or 
• ponovna pojava klinički značajnog krvarenja zajedno s produljenim vremenom zgrušavanja ili
PARTICULARS TO APPEAR ON THE OUTER PACKAGING FOLDING BOX 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU SKLOPIVA KUTIJA
Immediately after the administration of idarucizumab, the plasma concentrations of unbound dabigatran were reduced by more than 99 %, resulting in levels with no anticoagulant activity. 
Odmah nakon primjene idarucizumaba, koncentracije nevezanog dabigatrana u plazmi smanjile su se za više od 99%, što je rezultiralo razinama bez antikoagulacijske aktivnosti.
Additionally, no idarucizumab binding to human reproductive tissues was observed in a tissue cross-reactivity study. 
Pored toga, vezanje idarucizumaba na humana reproduktivna tkiva nije zapaženo u ispitivanju tkivne križne reaktivnosti.
Each 50 mL vial contains 2 g sorbitol and 25 mg sodium (see section 4.4). 
Jedna bočica od 50 ml sadrži 2 g sorbitola i 25 mg natrija (vidjeti dio 4.4).
Preclinical data reveal no special hazard for humans based on repeated dose toxicity studies of up to four weeks in rats and two weeks in monkeys. 
Neklinički podaci ne ukazuju na poseban rizik za ljude na temelju ispitivanja toksičnosti ponovljenih doza u trajanju do četiri tjedna u štakora i dva tjedna u majmuna.
Praxbind solution for injection/infusion is a clear to slightly opalescent, colourless to slightly yellow solution supplied in a glass vial closed with a butyl rubber stopper and an aluminium cap. 
Praxbind otopina za injekciju/infuziju je bistra do blago zamućena, bezbojna do blago žuta otopina dostupna u staklenoj bočici zatvorenoj čepom od butilne gume i aluminijskim zatvaračem.
These tests were used to assess the anticoagulant effect of dabigatran. 
Ove su se pretrage koristile za procjenu antikoagulacijskog učinka dabigatrana.
In a phase III trial the safety of Praxbind has been evaluated in 503 patients, who had uncontrolled bleeding or required emergency surgery or procedures and were under treatment with Pradaxa (dabigatran etexilate), as well as in 224 volunteers in phase I trials. 
U ispitivanju faze III, sigurnost Praxbinda se procjenjivala u 503 bolesnika koji su nekontrolirano krvarili ili su trebali biti podvrgnuti hitnom kirurškom zahvatu ili postupcima, a bili su na terapiji Pradaxom (dabigatraneteksilatom), kao i u 224 dobrovoljca u ispitivanjima faze I.
Preclinical investigations with idarucizumab have shown no interactions with 
Pretklinička istraživanja idarucizumaba nisu pokazala interakcije s
Pre-existing antibodies with cross-reactivity to idarucizumab were detected in approximately 12 % (33/283) of the phase I subjects and 3.8% (19/501) of the patients. 
Prethodno postojeća antitijela s križnom reaktivnošću na idarucizumab su otkrivena u približno 12% (33/283) ispitanika iz ispitivanja faze I i 3,8% (19/501) bolesnika.
Since dabigatran is also excreted primarily via the kidneys, increases in the exposure to dabigatran are also seen with worsening renal function. 
Budući da se dabigatran također izlučuje primarno putem bubrega, povećanja u izloženosti dabigatranu zapažena su i u bolesnika s pogoršanom funkcijom bubrega.
What Praxbind is and what it is used for 
Što je Praxbind i za što se koristi
Do not use this medicine after the expiry date which is stated on the vial and the carton after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na bočici i kutiji iza oznake „EXP“.
Praxbind contains sodium 
Praxbind sadrži natrij
The line must be flushed with sodium chloride 9 mg/ml (0.9 %) solution for injection prior to and at the end of infusion. 
Linija se prije i nakon završetka infuzije mora isprati otopinom natrijeva klorida od 9 mg/ml (0,9%) za injekciju.
It will not reverse the effects of other anticoagulants. 
On neće poništiti učinke drugih antikoagulanasa.
To reduce this risk, resumption of anticoagulant therapy should be considered as soon as medically appropriate. 
Radi smanjenja ovog rizika, potrebno je razmotriti nastavljanje terapije antikoagulansom čim je to medicinski prikladno.
Idarucizumab has been studied in 58 patients with varying degrees of hepatic impairment. 
Idarucizumab je ispitan u 58 bolesnika s raznim stupnjevima oštećenja jetre.
Three randomised, double-blind, placebo-controlled Phase I studies in 283 subjects (224 treated with idarucizumab) were conducted to assess the safety, efficacy, tolerability, pharmacokinetics and pharmacodynamics of idarucizumab, given alone or after administration of dabigatran etexilate. 
Provedena su tri randomizirana, dvostruko slijepa, placebom kontrolirana ispitivanja faze I na 283 ispitanika (224 liječenih idarucizumabom) kako bi se ocijenila sigurnost, djelotvornost, podnošljivost, farmakokinetika i farmakodinamika idarucizumaba, primijenjenog u obliku monoterapije ili nakon primjene dabigatraneteksilata.
A value in the normal range after administration of idarucizumab indicates that a patient is no longer anticoagulated. 
Vrijednost u normalnom rasponu nakon primjene idarucizumaba upućuje da bolesnik više nije antikoaguliran.
The transient proteinuria usually peaked about 4 h after idarucizumab administration and normalised within 12-24 hours. 
Prolazna proteinurija je obično dosegnula vršne vrijednosti oko 4 sata nakon primjene idarucizumaba, a normalizirala se unutar 12-24 sata.
Thus idarucizumab will not reverse the effects of other anticoagulants. 
idarucizumab neće poništiti učinke drugih antikoagulanasa.